A pharmaceutical formulation, comprising a phosphatidylcholine product of formula (I), wherein R1 is the residue of a saturated or unsaturated fatty acid with 12-24 carbon atoms, and R2 is the residue of a saturated or unsaturated fatty acid with 12-24 carbon atoms, and wherein the phosphatidylcholine product (PC) contains the following amounts of fatty acids: 55-72 linoleic acid； 10 18 palmitic acid； 07 15 oleic acid； 02 08 linolenic acid； 02 08 stearic acid, and at least one excipient for delayed release, can be used for the improved treatment of ulcerative colitis.
